FY2026 EPS Estimates for Elevance Health Boosted by Analyst

Elevance Health, Inc. (NYSE:ELV) – Analysts at Zacks Research lifted their FY2026 earnings per share (EPS) estimates for shares of Elevance Health in a research report issued to clients and investors on Tuesday, July 28th. Zacks Research analyst Team now anticipates that the company will post earnings of $27.06 per share for the year, up from their prior forecast of $26.79. The consensus estimate for Elevance Health’s current full-year earnings is $27.04 per share. Zacks Research also issued estimates for Elevance Health’s Q2 2027 earnings at $7.43 EPS, Q3 2027 earnings at $6.70 EPS, Q4 2027 earnings at $4.66 EPS, FY2027 earnings at $28.83 EPS, Q1 2028 earnings at $11.15 EPS, Q2 2028 earnings at $8.22 EPS and FY2028 earnings at $32.49 EPS.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. During the same quarter in the previous year, the business earned $8.84 earnings per share. The firm’s quarterly revenue was up .8% compared to the same quarter last year.

Several other research firms have also issued reports on ELV. Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. raised their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Leerink Partners lifted their target price on shares of Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Finally, Royal Bank Of Canada dropped their target price on shares of Elevance Health from $439.00 to $424.00 and set a “sector perform” rating on the stock in a research note on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and a consensus target price of $440.90.

Elevance Health Trading Up 1.9%

NYSE ELV opened at $385.67 on Wednesday. Elevance Health has a 12 month low of $273.71 and a 12 month high of $436.24. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68. The stock’s fifty day moving average price is $398.05 and its 200-day moving average price is $356.65. The stock has a market cap of $83.64 billion, a P/E ratio of 17.14, a P/E/G ratio of 2.18 and a beta of 0.67.

Institutional Trading of Elevance Health

A number of large investors have recently made changes to their positions in ELV. Bright Rock Capital Management LLC purchased a new stake in Elevance Health during the fourth quarter valued at $7,362,000. M&T Bank Corp lifted its holdings in Elevance Health by 160.4% in the fourth quarter. M&T Bank Corp now owns 50,486 shares of the company’s stock valued at $17,698,000 after acquiring an additional 31,101 shares during the period. HF Advisory Group LLC boosted its position in Elevance Health by 1,797.0% in the fourth quarter. HF Advisory Group LLC now owns 152,705 shares of the company’s stock worth $53,531,000 after purchasing an additional 144,655 shares during the last quarter. Solidarity Wealth LLC purchased a new position in Elevance Health in the fourth quarter worth about $1,433,000. Finally, Manning & Napier Advisors LLC grew its stake in shares of Elevance Health by 1,423.1% during the 4th quarter. Manning & Napier Advisors LLC now owns 368,426 shares of the company’s stock valued at $129,152,000 after purchasing an additional 344,237 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio (DPR) is 30.58%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.